Pyxis Oncology Inc (NASDAQ: PYXS) is -5.77% lower on its value in year-to-date trading and has touched a low of $1.42 and a high of $6.85 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PYXS stock was last observed hovering at around $1.44 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $1.47, the stock is -8.55% and -38.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing 2.08% at the moment leaves the stock -57.26% off its SMA200. PYXS registered -37.45% loss for a year compared to 6-month loss of -58.71%. The firm has a 50-day simple moving average (SMA 50) of $2.4212 and a 200-day simple moving average (SMA200) of $3.453475.
The stock witnessed a -3.29% gain in the last 1 month and extending the period to 3 months gives it a -53.92%, and is -15.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.96% over the week and 7.55% over the month.
Pyxis Oncology Inc (PYXS) has around 50 employees, a market worth around $87.41M and $16.15M in sales. Profit margin for the company is -355.24%. Distance from 52-week low is 3.52% and -78.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-33.19%).
The EPS is expected to grow by 41.13% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
125.0 institutions hold shares in Pyxis Oncology Inc (PYXS), with institutional investors hold 75.11% of the company’s shares. The shares outstanding are 59.45M, and float is at 41.13M with Short Float at 17.85%. Institutions hold 56.66% of the Float.
The top institutional shareholder in the company is DEEP TRACK CAPITAL, LP with over 4.18 million shares valued at $13.85 million. The investor’s holdings represent 8.1578 of the PYXS Shares outstanding. As of 2024-06-30, the second largest holder is LAURION CAPITAL MANAGEMENT LP with 3.86 million shares valued at $12.78 million to account for 7.5282 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.79 million shares representing 5.4317 and valued at over $9.22 million, while BALYASNY ASSET MANAGEMENT L.P. holds 4.997 of the shares totaling 2.56 million with a market value of $8.48 million.
Pyxis Oncology Inc (PYXS) Insider Activity
The most recent transaction is an insider purchase by Connealy Pamela Ann, the company’s CFO & COO. SEC filings show that Connealy Pamela Ann bought 88,850 shares of the company’s common stock on Nov 26 ’24 at a price of $1.96 per share for a total of $0.17 million. Following the purchase, the insider now owns 1.2 million shares.
